The Southeast Cancer Control Consortium, Inc. (SCCC) is a Community Clinical Oncology Program (CCOP) funded for the past 17 years by the National Cancer Institute (NCI). The SCCC is a consortium of 18 components/communities and 22 institutions in a five-state area of the southeast United States. The SCCC's long term objective is to bring state-of-the-art clinical trails and prevention programs for cancer to an arena of small community institutions to increase access to NCI- approved cancer programs. The catchment of the referral communities is estimated at 9.7 million, with demographics reflecting a low population density, limited socioeconomic and educational development, female percentage greater than 50%, and an African American to white population approximately twice the national average. This provides an opportunity to increase minority access and maintain inclusion of women to research studies. There are 121 physicians (medical oncologists, surgeons, radiation oncologists, and urologists) participating in the SCCC. Each institution has a physician designated as the """"""""Community Leader"""""""", responsible for locally coordinating participation in the SCCC program. Each Community Leader has a support team of personnel {oncology nurses and clinical research associates/CRAs) who are trained by the SCCC Operations Office staff, in proper procedures for compliance to federal and research base regulations. The community support teams'efforts are coordinated and monitored by the Community Leaders'counterpart, an oncology nurse or CRA, who is the local """"""""Study Coordinator."""""""" The SCCC Operations Office coordinates the consortium's activities by providing a telephone and email information service line for members'questions, fax machine communication, monitoring Institutional Review Board (IRB) approvals, facilitating protocol participation via weekly mailings and monthly protocol mailings, conducting on-site visits, providing data management training and continuing education programs, preparing grant applications and reports, and coordinating research base audits. The SCCC Operations Office provides the communities with research base studies, for both cancer treatment and prevention, from the eight CCOP research bases approved by NCI. Each community has these studies reviewed by their local IRB, all of which are approved by the Office for Human Research Protections (OHRP). The Community Leaders and Study Coordinators educate local members and facilitate implementation of these studies within the communities. Through the expansive consortium network, there is confidence that the SCCC program will significantly improve the quality of and access to NCI-approved state-of-the-art cancer care and prevention studies in the community setting. The goal is to be able to reduce the morbidity and mortality of cancer by overcoming ethnic, minority, gender, and socioeconomicbarriers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA045808-18S1
Application #
8544102
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J1))
Program Officer
Whitman, Cynthia B
Project Start
1987-07-01
Project End
2005-05-31
Budget Start
2004-08-27
Budget End
2005-05-31
Support Year
18
Fiscal Year
2012
Total Cost
$323,511
Indirect Cost
Name
Southeast Cancer Control Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7

Showing the most recent 10 out of 215 publications